Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat PK in Hepatic Impairment
NCT02536911Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliglustat in Gaucher disease (GD) (3 arms), sponsored by Sanofi. Primary endpoints: Maximum plasma concentration observed at 3 days and Area under the plasma concentration at 3 days. Started Sep 2015; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT02536911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536911.